Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 150

1.

Retrospective cohort study of bronchial doses and radiation-induced atelectasis after stereotactic body radiation therapy of lung tumors located close to the bronchial tree.

Karlsson K, Nyman J, Baumann P, Wersäll P, Drugge N, Gagliardi G, Johansson KA, Persson JO, Rutkowska E, Tullgren O, Lax I.

Int J Radiat Oncol Biol Phys. 2013 Nov 1;87(3):590-5. doi: 10.1016/j.ijrobp.2013.06.2055.

PMID:
24074933
2.

Fractionated stereotactic body radiation therapy for medically inoperable stage I lung cancer adjacent to central large bronchus.

Song SY, Choi W, Shin SS, Lee SW, Ahn SD, Kim JH, Je HU, Park CI, Lee JS, Choi EK.

Lung Cancer. 2009 Oct;66(1):89-93. doi: 10.1016/j.lungcan.2008.12.016. Epub 2009 Jan 24.

PMID:
19168260
3.

Stereotactic body radiation therapy of lung tumors: preliminary experience using normal tissue complication probability-based dose limits.

Song DY, Benedict SH, Cardinale RM, Chung TD, Chang MG, Schmidt-Ullrich RK.

Am J Clin Oncol. 2005 Dec;28(6):591-6.

PMID:
16317270
4.

Esophageal dose tolerance to hypofractionated stereotactic body radiation therapy: risk factors for late toxicity.

Stephans KL, Djemil T, Diaconu C, Reddy CA, Xia P, Woody NM, Greskovich J, Makkar V, Videtic GM.

Int J Radiat Oncol Biol Phys. 2014 Sep 1;90(1):197-202. doi: 10.1016/j.ijrobp.2014.05.011. Epub 2014 Jul 8.

PMID:
25015204
5.

Radiation-induced rib fractures after hypofractionated stereotactic body radiation therapy: risk factors and dose-volume relationship.

Asai K, Shioyama Y, Nakamura K, Sasaki T, Ohga S, Nonoshita T, Yoshitake T, Ohnishi K, Terashima K, Matsumoto K, Hirata H, Honda H.

Int J Radiat Oncol Biol Phys. 2012 Nov 1;84(3):768-73. doi: 10.1016/j.ijrobp.2012.01.027. Epub 2012 Mar 23.

PMID:
22445398
6.

Applicability of the linear-quadratic formalism for modeling local tumor control probability in high dose per fraction stereotactic body radiotherapy for early stage non-small cell lung cancer.

Guckenberger M, Klement RJ, Allgäuer M, Appold S, Dieckmann K, Ernst I, Ganswindt U, Holy R, Nestle U, Nevinny-Stickel M, Semrau S, Sterzing F, Wittig A, Andratschke N, Flentje M.

Radiother Oncol. 2013 Oct;109(1):13-20. doi: 10.1016/j.radonc.2013.09.005. Epub 2013 Oct 30.

PMID:
24183066
7.

Local control and toxicity in a large cohort of central lung tumors treated with stereotactic body radiation therapy.

Modh A, Rimner A, Williams E, Foster A, Shah M, Shi W, Zhang Z, Gelblum DY, Rosenzweig KE, Yorke ED, Jackson A, Wu AJ.

Int J Radiat Oncol Biol Phys. 2014 Dec 1;90(5):1168-76. doi: 10.1016/j.ijrobp.2014.08.008. Epub 2014 Oct 8.

8.

Stereotactic body radiotherapy for central lung tumors.

Rowe BP, Boffa DJ, Wilson LD, Kim AW, Detterbeck FC, Decker RH.

J Thorac Oncol. 2012 Sep;7(9):1394-9. doi: 10.1097/JTO.0b013e3182614bf3.

9.

Stereotactic body radiation therapy can be used safely to boost residual disease in locally advanced non-small cell lung cancer: a prospective study.

Feddock J, Arnold SM, Shelton BJ, Sinha P, Conrad G, Chen L, Rinehart J, McGarry RC.

Int J Radiat Oncol Biol Phys. 2013 Apr 1;85(5):1325-31. doi: 10.1016/j.ijrobp.2012.11.011. Epub 2012 Dec 19.

PMID:
23265574
10.

Predicting chest wall pain from lung stereotactic body radiotherapy for different fractionation schemes.

Woody NM, Videtic GM, Stephans KL, Djemil T, Kim Y, Xia P.

Int J Radiat Oncol Biol Phys. 2012 May 1;83(1):427-34. doi: 10.1016/j.ijrobp.2011.06.1971. Epub 2011 Dec 23.

PMID:
22197087
11.

[An analysis of 20 consecutive patients treated with stereotactic body radiotherapy on Novalis Tx(®) for stage I non-small-cell lung cancer].

Guillerme F, Clavier JB, Schumacher C, Falcoz PE, Bourrhala K, Santelmo N, Hassler S, Schott R, Quoix E, Massard G, Noël G.

Cancer Radiother. 2013 Jul-Aug;17(4):272-81. doi: 10.1016/j.canrad.2013.01.021. Epub 2013 May 24. French.

PMID:
23712043
12.

Radiation-induced rib fractures after hypofractionated stereotactic body radiation therapy of non-small cell lung cancer: a dose- and volume-response analysis.

Pettersson N, Nyman J, Johansson KA.

Radiother Oncol. 2009 Jun;91(3):360-8. doi: 10.1016/j.radonc.2009.03.022. Epub 2009 May 4.

PMID:
19410314
13.

A dose-volume analysis of radiation pneumonitis in non-small cell lung cancer patients treated with stereotactic body radiation therapy.

Barriger RB, Forquer JA, Brabham JG, Andolino DL, Shapiro RH, Henderson MA, Johnstone PA, Fakiris AJ.

Int J Radiat Oncol Biol Phys. 2012 Jan 1;82(1):457-62. doi: 10.1016/j.ijrobp.2010.08.056. Epub 2010 Oct 29.

PMID:
21035956
14.

Predictors of radiotherapy induced bone injury (RIBI) after stereotactic lung radiotherapy.

Taremi M, Hope A, Lindsay P, Dahele M, Fung S, Purdie TG, Jaffray D, Dawson L, Bezjak A.

Radiat Oncol. 2012 Sep 17;7:159. doi: 10.1186/1748-717X-7-159.

15.

Toxicity after central versus peripheral lung stereotactic body radiation therapy: a propensity score matched-pair analysis.

Mangona VS, Aneese AM, Marina O, Hymas RV, Ionascu D, Robertson JM, Gallardo LJ, Grills IS.

Int J Radiat Oncol Biol Phys. 2015 Jan 1;91(1):124-32. doi: 10.1016/j.ijrobp.2014.08.345. Epub 2014 Oct 18.

PMID:
25442337
16.

CyberKnife radiosurgery for stage I lung cancer: results at 36 months.

Brown WT, Wu X, Fayad F, Fowler JF, Amendola BE, García S, Han H, de la Zerda A, Bossart E, Huang Z, Schwade JG.

Clin Lung Cancer. 2007 Sep;8(8):488-92.

PMID:
17922973
17.

Dosimetric predictors of radiation-induced lung injury in stereotactic body radiation therapy.

Ricardi U, Filippi AR, Guarneri A, Giglioli FR, Mantovani C, Fiandra C, Anglesio S, Ragona R.

Acta Oncol. 2009;48(4):571-7. doi: 10.1080/02841860802520821.

PMID:
19031164
18.

Dose-volume parameters predict for the development of chest wall pain after stereotactic body radiation for lung cancer.

Mutter RW, Liu F, Abreu A, Yorke E, Jackson A, Rosenzweig KE.

Int J Radiat Oncol Biol Phys. 2012 Apr 1;82(5):1783-90. doi: 10.1016/j.ijrobp.2011.03.053. Epub 2011 Aug 23.

19.

Dose--volume metrics associated with radiation pneumonitis after stereotactic body radiation therapy for lung cancer.

Matsuo Y, Shibuya K, Nakamura M, Narabayashi M, Sakanaka K, Ueki N, Miyagi K, Norihisa Y, Mizowaki T, Nagata Y, Hiraoka M.

Int J Radiat Oncol Biol Phys. 2012 Jul 15;83(4):e545-9. doi: 10.1016/j.ijrobp.2012.01.018. Epub 2012 Mar 19.

20.

Lung stereotactic body radiation therapy (SBRT) delivered over 4 or 11 days: a comparison of acute toxicity and quality of life.

Jain S, Poon I, Soliman H, Keller B, Kim A, Lochray F, Yeung L, Cheung P.

Radiother Oncol. 2013 Aug;108(2):320-5. doi: 10.1016/j.radonc.2013.06.045. Epub 2013 Aug 27.

PMID:
23993401

Supplemental Content

Support Center